Exothera, which is specialized in the industrialization of vaccine and gene therapy processes, has successfully transferred IDT Biologika’s upstream process from small- to large-scale capability in the NevoLine Upstream platform of its parent company Univercells Technologies.

The NevoLine platform incorporates the scale-X structured fixed-bed bioreactor system that offers a range of options to upscale viral production from R&D to commercialization.

The partners said the innovative biomanufacturing technology will help to deliver cost-effective viral production. The collaboration between the two CDMOS is designed to demonstrate the application and increased performance of the platform at full commercial capacity.

Author: Dede Williams, Freelance Journalist